Search

Your search keyword '"Belhadj, Karim"' showing total 229 results

Search Constraints

Start Over You searched for: Author "Belhadj, Karim" Remove constraint Author: "Belhadj, Karim" Language english Remove constraint Language: english
229 results on '"Belhadj, Karim"'

Search Results

1. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

2. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

3. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

4. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

5. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France

7. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

8. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

9. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study.

11. Existence results to Steklov system involving the (p, q)-Laplacian

12. Existence and non-existence of solutions for a (p,q)-Laplacian Steklov system

13. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

14. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.

15. Heart Transplantation, Either Alone or Combined With Liver and Kidney, a Viable Treatment Option for Selected Patients With Severe Cardiac Amyloidosis

16. On a positive solutions for $(p,q)$-Laplacian Steklov problem with two parameters

18. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

19. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

20. RAS/RAF landscape in monoclonal plasma cell conditions

23. Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

25. Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

26. Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.

27. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

28. On a positive solution for $(p,q)$-Laplace equation with Nonlinear

29. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

30. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

31. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study

32. Existence and non-existence of positive solution for (p, q)-Laplacian with singular weights

33. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

34. Existence and multiplicity of $a$-harmonic solutions for a Steklov problem with variable exponents

35. Existence and multiplicity results for elliptic problems with Nonlinear Boundary Conditions and variable exponents

36. MM-491 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

37. Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

38. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.

40. Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa

41. Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

42. Existence of solutions for a Steklov proble involving the $p(x)$-Laplacian

43. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

45. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study.

46. Existence for an elliptic system with nonlinear boundary conditions

47. Eigenvalues of an Operator Homogeneous at the Infinity

48. Existence of solutions for a resonant Steklov Problem

49. The beginning of the Fucik spectrum for a Steklov Problem

50. Eigencurves for a Steklov problem

Catalog

Books, media, physical & digital resources